Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
The FDA has approved a second tracer, flutemetamol, for PET imaging of amyloid plaques in the brain.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Researchers Revel in C9ORF72 Advances at RNA Symposium Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS The Four Stages of TDP-43 Proteinopathy Blocking a MicroRNA Slows Motor Neuron Disease in Mice Glial Cells Refine Neural Circuits Innate Immune ...
A Conference Devoted to Better Engaging Clinical Trial Volunteers Turning to the Internet for Alzheimer’s Trial Volunteers Patient Engagement in Clinical Trials ...
New research reveals fundamental roles for astrocytes and microglia in shaping neural circuits.
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
The NIH releases whole-genome data from the Alzheimer’s Sequencing Project.
Thought to be no place for translation, RNA granules that form in “FUSopathies” turn out to host protein synthesis, after all.
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
No filters selected